tiprankstipranks
Advertisement
Advertisement

SE:ONCO Stock Latest News

Company AnnouncementsOncopeptides AGM Backs Incentive Schemes and Expands Capital-Raising Mandate
3d ago
PremiumCompany Announcements
Oncopeptides’ Pepaxti Shows Strong Phase 2 Data in Myeloma Patients With Renal Impairment
4d ago
PremiumCompany Announcements
Oncopeptides Wins Norwegian Green Light for Pioneering Glioblastoma Trial
5d ago
PremiumCompany Announcements
Oncopeptides showcases new Pepaxti data to bolster multiple myeloma positioning
11d ago
PremiumCompany Announcements
Oncopeptides posts strong Q1 sales growth as Pepaxti momentum builds in Europe
11d ago
PremiumCompany AnnouncementsOncopeptides Targets Third-Line Multiple Myeloma Indication to Boost Pepaxti Growth
13d ago
Premium
Company Announcements
Oncopeptides Sets May 13 Webcast for Q1 2026 Results
18d ago
Premium
Company Announcements
Oncopeptides Marks Growth Phase as 2025 Annual Report Highlights Pepaxti Momentum
26d ago
PremiumCompany Announcements
Oncopeptides Sets May Date and Rules for 2026 AGM Participation
1M ago
PremiumCompany Announcements
Oncopeptides Showcases Promising NK-Cell Engager Data for Multiple Myeloma at AACR 2026
1M ago
Oncopeptides Boosts Share Capital After Rights Issue to Support Cancer Drug Push
PremiumCompany Announcements
Oncopeptides Boosts Share Capital After Rights Issue to Support Cancer Drug Push
2M ago
Oncopeptides Raises SEK 190 Million in Partially Guaranteed Rights Issue
PremiumCompany Announcements
Oncopeptides Raises SEK 190 Million in Partially Guaranteed Rights Issue
2M ago
Oncopeptides Launches Real-World MARINA Study for Pepaxti in Germany
PremiumCompany AnnouncementsOncopeptides Launches Real-World MARINA Study for Pepaxti in Germany
2M ago
Real-World Data Bolsters Oncopeptides’ Pepaxti as Bridging Therapy in Multiple Myeloma
Premium
Company Announcements
Real-World Data Bolsters Oncopeptides’ Pepaxti as Bridging Therapy in Multiple Myeloma
2M ago
Oncopeptides Wins Fast-Track Status for First PDC Trial in Glioblastoma
Premium
Company Announcements
Oncopeptides Wins Fast-Track Status for First PDC Trial in Glioblastoma
3M ago
Oncopeptides AB Balances Growth, Cash Crunch in Earnings
PremiumCompany Announcements
Oncopeptides AB Balances Growth, Cash Crunch in Earnings
3M ago
Oncopeptides launches SEK 200m rights issue to fund Pepaxti rollout and glioblastoma push
PremiumCompany Announcements
Oncopeptides launches SEK 200m rights issue to fund Pepaxti rollout and glioblastoma push
3M ago
Oncopeptides Doubles 2025 Sales and Raises Capital to Drive Glioblastoma Push
PremiumCompany Announcements
Oncopeptides Doubles 2025 Sales and Raises Capital to Drive Glioblastoma Push
3M ago
Oncopeptides Sets Date for 2025 Year-End Results Presentation
PremiumCompany Announcements
Oncopeptides Sets Date for 2025 Year-End Results Presentation
3M ago
Oncopeptides Lifts 2025 Sales but Delays Cash-Flow Break-Even to 2027
PremiumCompany AnnouncementsOncopeptides Lifts 2025 Sales but Delays Cash-Flow Break-Even to 2027
4M ago
Oncopeptides Drug Pepaxti Shows Strong Efficacy in High-Risk Multiple Myeloma
Premium
Company Announcements
Oncopeptides Drug Pepaxti Shows Strong Efficacy in High-Risk Multiple Myeloma
5M ago
Oncopeptides AB Establishes Nomination Committee for 2026 AGM
Premium
Company Announcements
Oncopeptides AB Establishes Nomination Committee for 2026 AGM
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >